Redeye stands by its upbeat view on BioInvent following continued progress during recent months. Highlights include a licensing deal in China for BI-1206 and approval for the start of a clinical trial for BI-1808. We expect a major revenue boost and a profit for the current quarter due to higher milestone payments. We raise our estimates and our base case to SEK 3 (2.8).